Bifidobacterium lactis BB-12® is a well established and extensively researched live culture. In fact, it is thought to be the single most researched strain of the entire Bifidobacteria genus - a significant genus, predominantly found in the large intestine. Bifidobacterium lactis BB-12® is the most researched strain amongst those with constipation, but also has significant research in supporting immune health.

Research on the probiotic strain Bifidobacterium lactis BB-12®

A recent clinical trial, one of the largest ever to investigate a probiotic, provides more evidence in support of the use of Bifidobacterium lactis BB-12® in those with constipation specifically. The B. lactis BB-12® strain was put to the test in a research project that used over 1,200 participants from all over Europe, including France, the UK and Germany. The subjects were selected from a volunteer database, each of which were healthy and had never previously been diagnosed with acute digestive dysfunction, but had reported symptoms of low defecation frequency and abdominal discomfort.

The volunteers were split into 3 groups. The first received 1 billion dose of B. lactis BB-12® once daily. The second group received a 10 billion dose of B. lactis BB-12® once daily, and the third group received a placebo. The groups were tested for a period of 4 weeks.

Results showed that B. lactis BB-12 should certainly be considered as part of a solution to improve bowel regularity. The 1 billion B. lactis BB-12 group revealed the most statistically impressive result, improving defecation frequency from 3 days a week to 4.5 days a week.

"Once again, it is confirmed that the BB-12® probiotic strain can bring significant gastrointestinal benefits to those who experience digestive issues." Mikkel Jungersen, Scientific Advisor, HHN, Chr. Hansen
Read the full trial below...

Eskesen, D. et al. (2015) Effect of the probiotic strain Bifidobacterium animalis subsp. lactis BB-12, on defecation frequency in healthy subjects with low defecation frequency and abnormal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. British Journal of Nutrition.

Matsumoto, M. et al. (2001) Effect of Yoghurt with Bifidobacterium lactis Bb-12® in Improving Fecal Microflora and Defecation of Healthy Volunteers. Journal of Intestinal Microbiology; 14(2): pp. 97-102

Pitkala, K.H et al. (2007) Fermented cereal with specific Bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial. Journal of Nutritional Health and Aging; 11(4): pp.305-311.

Nishida, S. et al. (2004) Effect of Yoghurt Containing Bifidobacterium lactis BB-12® on Improvement of Defecation and Fecal Microflora of Healthy Female Adults. Milk Science; 53(2): pp. 71-80

Nishida et al (2004) clinical trial

  • Subject group of 20-39 year old women.
  • BB-12® shown to significantly increase stool frequency in those with constipation.
  • Those in the non-constipated group did not have too many bowel movements. BB-12® was able to harmonise regularity of bowel movements.

Murakami, T. et al (2006) Safety and effect of yoghurt containing Bifidobacterium lactis BB-12® on improvement of defecation and faecal microflora in healthy volunteers. Journal of Nutritional Food; 9 pp. 15-26

Uchida et al. (2005) Effect of fermented milk containing Bifidobacterium lactis BB-12® on stool frequency, defecation, fecal microbiota and safety of excessive ingestion in healthy female students. Journal of Nutritional Food. 8(1): pp.39-51

Rizzardini, G. et al (2011) Evaluation of the immune benefits of two probiotic strains Bifidobacterium lactis BB-12® and Lactobacillus casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study. British Journal of Nutrition

Click on this link for more research on Bifidobacterium lactis BB-12®.

Research on the prebiotic FOS

Paineau, D. et al. (2007) The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. British Journal of Nutrition. 99: pp. 311-318

Slevin, M. M. et al (2014) Supplementation with Calcium and Short-Chain Fructo-Oligosaccharides Affects Markers of Bone Turnover but Not Bone Mineral Density in Postmenopausal Women. The Journal of Nutrition. Published online ahead of print.